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ABSTRACT 
INTRODUCTION 
Worldwide, Gastric cancer is the second most common type of cancer. 
Of the gastric cancer, adenocarcinoma is the most common malignancy. It 
comprises over 90% of all gastric cancers. Gastric mucins are synthesized by 
gastric epithelial cells which are cytoprotective. Mucins are glycoprotein with 
high molecular weight, which are membrane bound or secreted products 
synthesized by secretory epithelial cells. Mucins in general are classified as 
neutral and acidic. Normal gastric mucin is of neutral type. In neoplastic 
transformation of gastric mucosa, the neutral mucin production is decreased.. 
More than 15 mucin genes have been identified. MUC-1 expressed in tumor 
may function as an anti-adhesion molecule that inhibits cell to cell adhesion, 
inducing the release of cells from the tumor. In these manners MUC-1 
expression may be associated with invasive or metastatic properties of tumor 
cells, resulting in poor prognosis for patients with gastric carcinoma showing 
MUC-1 expression. 
AIM 
To study the expression of MUC1 in gastric carcinomas and its 
correlation with the clinico pathological variables. 
 
 
MATERIALS AND METHODS 
From the period June 2013-2015 ,of the 126 gastrectomy specimens 
received, 50 cases of  gastrectomy specimens were subjected to 
immunohistochemistry marker, MUC1 and  analysed with various 
clinicopathological  parameters including age, sex, site, gross type, histological 
type, grading, TNM staging, lymphocytic infiltration, lymphovascular invasion, 
perineural invasion and its correlation with MUC1 Mucin,  expression and the 
results were tabulated and statistically evaluated . 
 
RESULTS 
                  In the study period of 2 years from June 2013-June 2015, Gastric 
cancer had a peak incidence in the age group of  51 – 60 years, with the mean 
age of 55.5 years with 70% - in males and 30% in females. Males predominate 
in the ratio of 2 .3 : 1 . On immunohistochemistry with MUC1,the expression 
was membranous / cytoplasmic positivity (graded as 1+, 2+, 3+, Negative) 
which was seen in 64% of cases. An increase in expression of MUC1  
positivity was seen with increasing age and intestinal type of gastric 
adenocarcinomas. 
 
KEY WORDS 
Gastric Adenocarcinoma, anti-adhesion, MUC1 expression, 
cytoplasmic. 
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INTRODUCTION 
Worldwide, Gastric cancer ranks the second most common cancer and in 
India it is third most common1 .  Among different continents there were wide 
variations in incidence and in Asia2, 3 incidence was the highest, followed by 
central Europe and South America. In recent years changes were seen in 
topographic distribution of gastric carcinomas. The frequent detection of 
superficial gastric cancers has been made easy with the widespread use of 
upper gastrointestinal endoscopy. This made an impact on the gastric cancer 
mortality rate, as carcinomas detectable at an early stage were potentially 
curable4. 
There was a wide variety of morphological phenotypes in gastric 
carcinoma. The prognosis not only rely on the histological appearances of the 
tumor alone, but rather depend mainly on the staging (ANNEXURE-II)  system 
of the tumor. Accounting for this variability in prognosis, among the clinical 
and pathological staging, there was a routine search for the biological markers, 
specifically to find the category of patients having aggressive disease course5 
.In this study, the biological behaviour of gastric cancer  has been studied using 
the immuno histochemical expression of protein MUC-1 Mucin.  
MUC-1, Mucin is a trans membrane glycoprotein with an extracellular 
domain consisting of a variable number of highly conserved tandem repeats of 
20 aminoacids, a trans membrane domain and a cytoplasmic tail of 69  
aminoacids6,7,8,9,10. 
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MUC-1 expressed in tumor may function as an anti-adhesion molecule 
that inhibits cell to cell adhesion, inducing the release of cells from the 
tumor11,12. In this manner MUC-1 expression may be associated with invasive 
or metastatic properties of tumor cells, resulting in poor prognosis for patients 
with gastric carcinoma showing MUC-1 expression. 
Carcinoma associated with MUC-1 and synthetic tandem repeats of   
MUC-1 mucin core peptide, suppress human T cell proliferative response and 
the   high levels of MUC-1 mucin are correlated with immunosuppression in 
adenocarcinoma patients and this immunosuppression by MUC-1 result in poor 
prognosis of gastric carcinoma patients13. 
Hence the patients expressing MUC-1 mucin have poorer prognosis and 
aggressive tumor behavior. Thus the routine evaluation of  mucin MUC-1 
could be useful in identifying patients with aggressive disease and contribute to 
a better  therapeutic approach .     
In this study of 50 cases, an attempt is made to study the expression of 
MUC-1 immunohistochemically and to compare it with the parameters 
clinicopathologically. 
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AIMS AND OBJECTIVES 
 
1) To identify the incidence and distribution of gastric carcinoma in 
patients admitted in Government General Hospital, Chennai from June 
2013 to June 2015.  
2)  To study the histomorphological features of gastric carcinoma including 
tumor size, tumor location, macroscopic appearance, histological type, 
grade, depth of infiltration, lymph node status, stage ,presence of  
lympho-vascular invasion, perineural invasion, lymphocytic response.  
3)  To study the immunohistochemical expression of MUC-1 in gastric 
carcinoma. 
4)  To determine the correlation of MUC-1 expression with known 
prognostic factors such as tumor size, histological type, grade, depth of 
infiltration, lymph node status, stage, presence  of  lymphocytic 
infiltration, lympho-vascular invasion and perineural invasion.  
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REVIEW OF LITERATURE 
ANATOMY14 
Stomach is a variable sized distensable bag located a few centimeter 
below the diaphragm. It is divided into 5 regions .An ill defined area connects 
the G.E junction is the cardia. The portion of stomach below  cardia is the 
fundus .The main portion which lies below the fundus  is the body or corpus. 
The distal portion is the antrum , separated approximately at the incisura 
anguaris from the body. The distal most is the narrow channel (1-2cm) the 
pylorus, which follows the antrum ,connects stomach with the duodenum. 
HISTOLOGY14 
In view of its epithelial components ,stomach is a complex organ. 
Mucosa of stomach is fundic and antral type. 
Fundic type mucosa is seen in fundus and body. It consists of fundic or 
oxyntic glands, which constitutes approximately 80% of the mucosal thickness. 
The superficial cells (20%) consists of tall columnar  foveolar cells which 
produce neutral mucin .The fundic glands are composed of parietal cells 
secreting acid and  Zymogen (chief )cells secreting pepsin. Antral type mucosa 
is seen in the antrum, pylorus and cardia, where the loosely packed deeper 
glands secrete mucin. In antral type mucosa the ratio of mucinous glands to 
overlying foveolae is roughly 1:1. 
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The lamina propria is composed of inflammatory cells comprising of 
only a minimal number of lymphocytes, eosinophils , plasma cells and mast 
cells. 
The sub mucosa is composed of loose connective tissue containing 
numerous elastic fibers , arteries ,veins , meissner’s nerve plexus and lymph 
vessels.  
The muscularis propria consists of  inner circular and outer longitudinal 
layer and the outer most layer is the serosa . 
GASTRIC CARCINOMA  
INTRODUCTION 
Gastric carcinoma are malignant tumors of stomach arising from gastric 
glandular epithelium. In 1600 BC, the first case of gastric cancer was reported 
in Ebers papyrus and in the second century AD in the Hippocrates reports 
related by Galen in Rome15 .A possible description of a gastric cancer could be 
read in Avicenna’s medical encyclopedia ,at the end of the first millennium 
AD. Despite this in the 18th century, gastric cancers were largely unknown 
because benign and malignant gastric ulcers were only described later by 
J.Cruveilhier, in 1835. 
The official history of gastric cancer surgery began 40 years later,when 
Jules Emile Pean, a very famous French surgeon , performed the first gastric 
resection for cancer in 187916,during which the official history of gastric cancer 
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surgery began. In 1881,In veinna the first successful subtotal resection with 
gastro duodenal anastamosis was performed by Theodor Billroth17. 
CLASSIFICATION 
The most common malignancy of  stomach is the adeno carcinoma, 
accounting to 90% of all gastric cancers .Several  systems of classification 
were proposed later. Lauren classification was one of the earliest proposed in 
1965,enumerates 2 types of gastric carcinoma -Intestinal and Diffuse 
type18.Followed by Ming in 1977,divided adeno carcinoma into 2 types based 
on growth pattern 1) Expanding and 2) Infiltrative. And In 1977 WHO 
classification (ANNEXURE-III) was proposed based on histomorphology. 
EPIDEMIOLOGY 
Incidence of gastric carcinoma varies with geography. It is up to 20 fold 
higher in Japan, Coast Rica, Chile, Eastern Europe when compared to Northern 
Europe, North America, South East Asia and Africa. In high incidence region 
like Japan,35% of newly detected cases were of early gastric cancer (i.e) tumor 
limited to mucosa and sub mucosa. This is because of mass endoscopic 
screening programs14.Japan and Korea have the highest gastric cancer rate in 
the world19.   Based on the study of National cancer Registry program of India 
in 2001,the number of new Gastric cancer were approximately 35,675 (n-
23,785 in Males,11890 in Females)20. 
Southern part of India has four times higher incidence rates of gastric 
cancer when compared to Northern parts. In southern part of India, among the 
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six registries, Gender wise higher incidence rate was reported from Chennai for 
both the genders and the age standardized incidence rates are 13.6/100,000 in 
Males and 6.5/100,000 in Females20.On Comparing Five year survival rates ,it 
was higher up to 95% in early gastric cancers, whereas 10 to 20% in advanced 
gastric cancers 21. 
AGE AND SEX 
Gastric carcinomas are very rare in less than 40 years of age. It is more 
common in older age group in both the sexes. In Males, intestinal type is more 
common, whereas in Females and younger individuals diffuse type is the most 
common type 22. 
ETIOLOGY 
HIGH RISK FACTORS 
Low socio economic status, salt intake, smoked meat or fish, pickled 
vegetables, soya beans , peppers, and Host factors, Helicobacter pylori have 
high risk for developing gastric carcinoma. 
DIET 
The diets mentioned above have low level of micronutrients, 
antioxidants, vitamins, and these favors the intraluminal formation of genotoxic 
agents such as N- nitrosocompounds that lead to the development of gastric 
carcinoma. 
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H.pylori 
Long standing H. pylori infection results in chronic gastritis, atrophic 
gastritis and intestinal metaplasia which result in increased risk of intestinal 
type of gastric carcinoma. 
In people having Blood Group A, and in those having family history of  
gastric cancer or pernicious anemia there is high incidence of gastric 
adenocarcinoma ,Diffuse type. 
LOWEST RISK 
Individuals with consumption of fresh fruits, vitaminC rich foods, 
vegetables, carotenoids, folates, tocopherols are found to have lowest risk of 
developing gastric cancer. 
PATHOGENESIS 
Germline mutation in CDH1 encodes E-cadherin protein that contributes 
to epithelial intercellular adhesion. It is usually associated with familial gastric 
cancer, mainly of diffuse type. CDH1 mutations are also seen in about 50% of 
sporadic cases of diffuse type gastric carcinomas. Also individuals with 
BRCA2 mutations are at increased risk of developing gastric cancer diffuse 
type23. 
Mutation of beta catenin, a protein that binds to both  E-cadherin and 
APC is seen in intestinal type of gastric cancer23.Microsatellite instability and  
hypermethylation of several genes including BAX, TGFbetaRII, IGFRII and 
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INK 4a/P16 also contribute to gastric cancer intestinal type. P53 mutation is 
present in majority of sporadic gastric cancer of both types. 23 
Patients having mutations of DNA mismatch repair genes and with 
HNPCC have increased frequency of gastric cancer24.Patients with Peutz -
jegher’s syndrome also show an increased risk of gastric cancers25. 
Gastric carcinogenesis26 is a multistep and multi factorial process that 
involve progression from   
NORMAL MUCOSA 
CHRONIC GASTRITIS 
ATROPHIC GASTRITIS 
INTESTINAL METAPLASIA 
 
DYSPLASIA 
 
CARCINOMA 
LOCALIZATION / TOPOGRAPHY OF GASTRIC CARCINOMA 
Distal stomach in antro pyloric region and along the lesser curvature is 
the most common site of gastric cancer. Recently cardiac region of stomach is 
found to have more incidence. Carcinomas of  corpus may be  located either on 
the Greater or Lesser curvature. 
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Early Gastric cancers are more commonly seen along the lesser 
curvature in the middle part of stomach, whereas Advanced gastric cancers are 
more common in antral region followed by corpus region. 
EARLY GASTRIC CANCER (EGC) 
This is limited to the mucosa or sub mucosa only, irrespective of  
lymphnode status. After histological examination EGC is subdivided into two 
group. Intra mucosal and Sub mucosal carcinoma. The presentation is 
somewhat at lower age 27  and generally the duration of symptoms are longer28. 
Early gastric cancer are otherwise called as surface carcinoma29, superficial 
spreading carcinoma30  and Cancer gatrique au de’but30.The term early gastric 
cancer denotes that the gastric cancer is potentially curable and does not denote  
the genesis of the cancer32.In countries like Japan, it is due to the routine and 
regular screening programs ,that the increasing numbers of early gastric 
cancers are being detected. 
ADVANCED GASTRIC CANCER (AGC) 
By definition this type of cancer has spread beyond the sub mucosa into 
muscularis propria and beyond,irrespective of lymphnode status. The term 
advanced indicate that treatment of this tumor is very difficult and they have 
decreased survival and it does not denote the higher stage of the disease. 
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PRE CANCEROUS  CONDITIONS 
1) Epithelial polyp 
2) Chronic atrophic gastritis –More common condition leading to 
carcinoma 
3) Chronic ulcer 
4) Intestinal metaplasia 
5) Gastric remnants 
6) Hyperplastic Gastropathy 
CLASSIFICATION OF INTESTINAL METAPLASIA 
Based on their cell type and functional features  it is divided into 2 types 
1) Complete and 2) Incomplete 
Complete Intestinal Metaplasia 
Gastric mucosa assumes the appearance of small intestine without villi. 
Glands are lined by absorptive cells,goblet cells, paneth cells, endocrine cells. 
Mucin can be sulphomucin ,sialomucin or both. 
Incomplete Intestinal Metaplasia 
Instead of absorptive cells, columnar cells between the goblet cells 
resemble foveolar mucus cells. Mucin can be neutral, sulphomucin or 
sialomucin. 
 
 RECENT CLASSIFICATION OF 
TYPE I-Complete intestinal metaplasia
TYPEII-Incomplete intestinal metaplasia
TYPE III-Incomplete intestinal metaplasia with predominant sulphated 
mucin. 
MACROSCOPIC APPEARANCE OF GASTRIC CANCER
          Japanese Gastroenterologica
classification for gross app
macroscopic appearance on endoscopy and in gastrectomy specimens.
were divided into 3 main types and 
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INTESTINAL METAPLASIA
 
 
l endoscopic society devised a sub
earance of early gastric cancer
3 subtypes 
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 based on  
 They 
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TYPE I – Protruded-The tumor projects clearly into the lumen and                       
  includes all polypoid ,nodular and villous tumors 
TYPE II – Superficial-This is further subdivided into 3 
                  TYPE II a - Elevated above surrounding mucosa by few                         
                                    millimeter,seen as well circumscribed flat plaque. 
                  TYPEII b - Macroscopically no visible abnormality. Flat. 
                  TYPEII c –Depressed. Surface slightly depressed below the  
                                     adjacent mucosa 
TYPEIII – Excavated-Ulceration of variable depth into the gastric wall. 
Macroscopic types of advanced gastric cancers can be understood from 
the scheme depicted by Dr. Bormann, who was a German Surgeon and a 
pathologist 
TYPE I –Polypoid / Nodular 
TYPEII –Ulcerative, localized/ fungating 
TYPEIII –Ulcerative, infiltrative 
TYPEIV –Diffusely, infiltrative                                             
 Ulcerated tumors most commonl
region. The ulcers are large with raised rolled 
necrotic shaggy base
body of stomach, greater curvature,
cancers produce plaque like lesions,
mucosa. It is accompanied 
the Leather bottle stomach or the so called Linitis 
carcinomas gives the gelatinous appearance secreting co
mucin, (so called col
Gastric adenocarcinomas are either gland forming tumors composed of 
tubular, papillary or acinar patterns or they 
of isolated or discohesive cells
14 
y occur in the lesser curvature,
out edges, irregular margins and 
33
.Polypoid, Nodular and fungating tumors occur in the 
 posterior wall or fundus.
 spread superficially in the 
by thickness of entire wall of the stomach producing 
plastica
nsiderable amounts of 
loid carcinomas.) 
are composed of complex
34
. 
 
 antral 
 Infiltrative 
mucosa and sub 
. Many Gastric 
 mixture 
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Several classification systems were proposed and they include Ming, 
Carniero and Goseki. Despite these the most commonly used were those of           
WHO35 (ANNEXURE III) Classification and Lauren. 
WHO CLASSIFICATION 
Tubular Adenocarcinoma 
Tubular adenocarcinoma composed predominantly of neoplastic tubules 
often showing irregular branching and anastomosis embedded in or surrounded 
by fibrous stroma. The neoplastic cells are columnar, cuboidal or flattened with 
intraluminal mucin. The degree of cytological atypia varies from low to high 
grade. An oncocytic variant of this type and poorly differentiated variant 
sometimes called as solid carcinoma has been described36. 
Papillary Carcinoma 
These are well differentiated carcinomas with papillary architectures 
which are elongated finger like processes lined by cuboidal cells with central 
fibrovascular core composed of connective tissue .Tubular differentiation may 
also been seen in this tumor referred as papillotubular. Micropapillary 
architecture has been seen rarely. Polypoid mass into the lumen of the stomach 
is the typical appearance of this tumor. 
Mucinous Carcinoma 
According to WHO, carcinomas containing more than 50% of 
extracellular mucin are called as mucinous carcinomas .In this there are two 
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sub types 1) The neoplastic cells form glands lined by columnar mucous 
secreting cells called as well differentiated type.2) In this there are 
disaggregated ribbons or clusters of cells which appear to be floating in the 
lakes of mucin referred to as poorly differentiated type. Mucin may be seen in 
the inter glandular stroma , scattered signet ring cells when present ,do not 
dominate the histological picture. They most commonly occur as polypoid , 
ulcerative ,or fungating masses. 
Signet Cell Carcinoma 
According to WHO this type of tumor is defined as carcinomas 
composed predominantly of single cells or small clusters of cells containing 
intra-cytoplasmic mucin vacuoles and accounting for more than 50% of the 
tumor. A classical signet ring cell appearance was due to an expanded, globoid, 
optically clear cytoplasm and the cells contain nuclei which push against cell 
membranes. These contain acid mucin and stain with Alcian blue at  PH 2.5.  
There are also cells with no mucin and cells with eosnophilic granular 
cytoplasm containing neutral mucin .This tumor is most commonly seen in 
younger patients and in distal stomach. The signet ring cell carcinomas tend to 
infiltrate the stomach wall diffusely and are accompanied by marked fibrosis 
giving rise to Linitis Plastica appearance in gross examination. 
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LAUREN’S CLASSIFICATION 
Lauren18 (1965) classified gastric adenocarcinomas histologically into 
two main types Intestinal and Diffuse .And those tumors having equal 
proportion of these two components are called as Mixed carcinomas. 
Carcinomas that are too undifferentiated to fit in either of these category are 
placed in Indeterminate category. 
INTESTINAL TYPE 
Intestinal type tumors have a glandular pattern usually accompanied by 
tubules ,papillary formations or solid components. The glands range from well 
differentiated to moderately differentiated grade. Sometimes poorly 
differentiated tumor at the advanced margins. The glandular epithelium is 
composed of  pleomorphic cells with large hyperchromatic nuclei often with 
numerous mitoses. The adjacent gastric mucosa often shows chronic gastritis 
,with widespread intestinal metaplasia and sometimes dysplasia. Intestinal type 
are commoner in the elderly and males. 
DIFFUSE TYPE  
These are predominantly composed of poorly cohesive diffusely 
infiltrating small tumor cells with indistinct cytoplasm and hyperchromatic 
nuclei, glandular formation may occur in the superficial part of the tumor. 
Signet ring cells are common and there may be extracellular mucin in the 
stroma. Desmoplasia is more pronounced and there may be no accompanying 
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metaplasia or dysplasia .Diffuse tumors usually occur at an younger age groups 
with equal sex incidence. 
MING CLASSIFICATION 
This expands Lauren’s classification by adding pyloro cardiac gland 
carcinoma38 a third type. These present as well demarcated fungating tumors. 
These tumors are commoner in men, and are characterized microscopically by 
varying sized glands showing tubular or papillary pattern .Cells that often show 
striking vacuolation or clear cell change and stain brilliantly with periodic acid 
Schiff reaction. 
GOSEKI CLASSIFICATION 
           This classification of gastric cancers by Goseki based on the degree of 
differentiation into tubules and the amount of mucin present intracellularly39 
and divided into four histological types. 
           GROUP I- Well differentiated tubules with poor intracellular  
            Mucin 
          GROUPII- consists of well differentiated tubules with plentiful    
            intracellular mucin 
          GROUPIII – consists of poorly differentiated tubules and poor  
                     intracellular mucin 
         GROUP IV- consists of poorly differentiated tubules and plentiful of  
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                     intracellular mucin 
CARNEIRO CLASSIFICATION 
This classification by Carneiro et al is a much simpler one in which the 
division comes as glandular,solid,isolated cell carcinomas  and a mixed type 
which have a mixture of both glandular and isolated cells34. 
RARE VARIANTS 
Adenosquamous carcinoma40 
           Squamous cell carcinoma41 
           Hepatoid adenocarcinoma42 
           Choriocarcinoma43 
           Medullary carcinoma with lymphoid stroma44 
           Small cell carcinoma45 
           Parietal cell carcinoma46 
           Gastric carcinoma with rhabdoid differentiation47 
           Carcinosarcoma48 
SPREADING OF GASTRIC CARCINOMA 
           Spreading of gastric cancer is particularly common with diffuse 
carcinomas and signet ring cell type carcinomas, in which spreading occur 
directly by penetrating the serosa and organ infiltration like liver, spleen, 
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pancreas, transverse colon and omentum. The depth of invasion of wall of the 
stomach directly correlates with the incidence of lymphatic spread. The 
lymphnodes which are commonly involved are nodes of left gastric, common 
hepatic, pancreatic, splenic and celiac artery .If  there is more distant spread, it 
involves mesenteric and para aortic nodes. The spread to left supra clavicular 
nodes via the thoracic duct (nodes of troisier and virchow) is not uncommon. 
            The spread by hematogenous route most commonly involves liver, 
followed by lung ,peritoneum,adrenal,skin and ovary( krukenberg tumor).The 
unusual sites such as kidney,spleen,uterus and meninges are involved in diffuse 
type of gastric carcinomas49. 
STAGING OF GASTRIC CANCER 
The TNM staging system50 (ANNEXURE II) is widely used in western 
countries. It is recommended and is the best available predictor of prognosis. 
PROGNOSIS 
           The prognosis of gastric cancer varies according to different countries 
with the best results of overall 5 year survival rate of 46% for advanced and 
89% for early gastric carcinomas in Japan51.In western countries the overall 
survival rate is between 4% and 13%52.According to a recent study which 
indicated there was 63%cumulative 5 year risk of progression into advanced 
cancer, from an untreated early gastric cancer53. 
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PROGNOSTIC FACTORS 
Any variable, which provides information, that are useful to assess the 
outcome of the disease at the time of diagnosis are called as prognostic factors. 
They are classified into clinical, morphological, genetic/molecular factors. 
           The clinical factors associated with poor prognosis are  younger age 
,large tumor size and gastric cancers at the proximal region52.For the cardia 
tumors the 5 year survival rates are under 20% 54 and 7 months of median 
survival only55. 
            The pathological factors playing a key role in prognosis assessment are 
as follows 
1) Stage  Of  The Tumor 
           It is the most significant factor , which incorporates the depth of 
invasion, the deeper the penetration ,the greater the chance of metastasis. This 
feature directly correlates with gross appearance of the tumor, such as the large 
intra luminal mass have lower rates of metastasis than those  growing  
primarily within the wall. 
2) Microscopic Type And Grading Of The Tumor 
Lauren’s Intestinal type of tumors behave relatively better than diffuse 
types56. 
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3)  Regional Nodal Involvement 
            With nodal positive cases, the 5 year survival rate drops to less than 
10% when compared to node negative cases with 50% survival. The involved 
number of nodes is a prognostically significant factor. As the number of 
positivity in lymph node   increases, the overall survival rate decreases57. 
4) Size Of The Tumor 
           Though smaller size tumors are associated with better prognosis, it is 
linked closely with the depth of invasion /penetration51. 
5) Lymphatic Invasion 
It is associated with poor prognostic indicator and strong association 
with nodal metastasis and poor patient survival. 
6) Vascular Invasion-   
The tumor cells infiltrate into the vascular spaces. Vascular invasion is 
the predictor of visceral metastasis and recurrence. 
      7) Perineural Invasion 
           It is the sign of poor prognosis 
           Other than the above mentioned factors ,poor prognostic factors include 
tumor necrosis, infiltrative tumor margins and surgical margin infiltration by 
tumor cells.  
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          In the study done by Y.E. Joo77 et al the mean age of  gastric carcinoma 
was 58.7 years with a range from 28 to 79 years , an average tumor size of  5.2 
cm and nodal metastasis in 51.3% cases . 
          In the study done by Nobuyuki Igarashi et al the incidence of gastric 
cancer in men and women was 74.1% and 25.9% respectively. 
           In the study of N.E. Tzanakis et al74 51.6% tumors in the antrum , an 
average tumor size of 5.1 cm 
            Daniela Lazar et al75 in his study observed 8.2% of Bormann type I 
tumors, 32.7% of type II tumors, 36% of type III tumors and 14.7% of type IV 
tumors, observed 50.8% tumors in the antrum. and the most common 
histological subtype of gastric cancer is Tubular carcinoma. 
           The most common histological subtype of gastric cancer is Tubular 
carcinoma Y.Kakeji et al78. The most common histological subtype (Lauren’s) 
based on the observations of the study  made by Casasola et a80 was the 
intestinal type.  
A higher proportion of T3 tumors, closely followed by T2 tumors were 
observed in the study of Giovanni de Manzoni et al81, and Y.E. Joo et al77. 
the study by Czyzewska J et al 79 nodal metastasis was observed in 55.6% of 
cases. 
Many molecular biomarkers, play a significant role in gastric carcinoma 
management.40 to 50% of gastric carcinoma show DNA Aneuploidy and they 
have significant association with both distant metastasis and lymphnode 
metastasis. Aneuploid tumors have lower survival rate than diploid 
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tumors58.HER2neu/c erb2,a trans membrane epidermal growth factor  receptor 
protein, over expression are known to be associated with poorer 
outcome59.Germline mutations of E-cadherin gene (CDH-1),which plays a role 
in maintenance of intercellular connections are associated with highly 
aggressive diffuse type gastric cancers60.Increased cathepsin D expression 
,increased proliferation indices and loss of F hit protein are associated with 
decreased survival.MUC-1,Mucin a trans membrane glycoprotein, expressed in 
tumors may function as anti-adhesion molecule, that inhibits cell to cell 
adhesion inducing release of tumor cells11,12.In these manners,MUC-1 
expression may be associated with invasive or metastatic properties of tumor 
cells, resulting in poor prognosis for patients with gastric carcinomas. 
MUCIN PROFILE IN STOMACH 
           Gastric mucins are synthesized by gastric epithelial cells which are 
cytoprotective. Mucins are glycoprotein with high molecular weight ,which are 
membrane bound or secreted products synthesized by secretory epithelial 
cells61. 
 A tandem repeat region rich in threonine /serine are characteristic of 
mucins which are O- glycosylation sites. The difference in tandem repeat 
sequence length and non repetitiveness makes each mucin an unique and 
distinct entity62. 
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           Mucins in general are classified as neutral and acid mucin of these, Acid 
mucins are of two types 
       1) Sulphated /sulphomucin and 
       2) Carboxylated/sialomucins 
Normal gastric mucin is of neutral type .Small amount of acid mucins 
such as sialomucin, sulphomucin are produced in foveola, neck cells of the 
fundus,  foveola of antrum and cardiac glands of stomach62,63. 
           In neoplastic transformation of gastric mucosa, the neutral mucin 
production is decreased. In intestinal metaplasia, a common precursor 
condition of carcinoma stomach62, the transition to acid mucin from neutral 
mucin occurs. These acid mucin produced during transition stage and gastric 
adenocarcinoma are predominantly of sulpho mucin type. 
Sulphomucin an acid mucin, characteristic of mature surface mucin cells 
are predominantly seen in well differentiated adenocarcinoma. The sialomucin, 
also an acid mucin, characteristic of  intestinal goblet cells 64 are seen 
predominantly in moderately differentiated and poorly differentiated 
adenocarcinoma. 
           The mucin secreted in mucinous adenocarcinoma are O acylated form of 
sialomucin, acidic mucin. This variant has good prognosis than the Signet ring 
cell carcinoma stomach. 
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          By special stain studies acid mucin and neutral mucin are clearly 
identified, such as PAS-periodic acid Schiff, combined Alcian blue Ph 2.5 
PAS. 
MUCIN GENE EXPRESSION IN NORMAL GASTRIC MUCOSA AND 
GASTRIC ADENOCARCINOMA 
          Human gastric epithelium has an unique mucin gene pattern which 
becomes altered markedly in pre neoplastic and neoplastic conditions. More 
than 15 mucin genes have been identified and they are categorized into  
1) Membrane Associated Mucin  
                      MUC1,3,4,12,13,15,16,17,20 
2) Gel Forming Mucin 
                      MUC2,5AC,5B,6 
3) Soluble Form 
                      MUC7 
In normal stomach MUC1,MUC5AC increased expression is seen in 
surface epithelium. MUC6 seen in deep gastric glands. 
MUC-1 
           Expressed in apex of the cell .It has inhibitory role in cell to cell 
adhesion, cell to stromal interaction and cytotoxic immunity. By interacting 
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with EGFR it functions as a signal transducer and participates in 
carcinogenesis. 
It is the marker for aggrssiveness.MUC-1 is also called as polymorphic 
epithelial mucin (PEM). 
           MUC-1 belongs to the mucin family (MUC-1 to MUC21), MUC-1 
protein on cell surface consists of  N- and C- terminal submits designated as 
MUC1-N and MUC1-C respectively 66,67. 
MUC-1 FUNCTION IN GASTRIC CARCINOGENESIS66, 67 
                  Contrary to its protective function in normal gastric epithelial cells, the 
gene is silenced in intestinal metaplasia, a pre-neoplastic lesion. Indeed MUC-1 
has been considered as an oncoprotein, because there is accumulating evidence 
which suggests its cancer promoting function. 
Moreover MUC1 could have some role in gastric carcinoma stem cells, 
as it acts as a growth factor receptor on undifferentiated human embryonic stem 
cells and is expressed in AML stem cells. Intriguingly, it is also known that 
MUC1 facilitates cancer cell survival under hypoxic and nutrient deprived 
conditions by regulating glucose and lipid metabolism and the cellular energy 
state. 
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RELATIONSHIP BETWEEN MUCIN AND PROGNOSTIC 
INDICATORS6 
To obtain a more precise relation between mucin and prognostic indicators, 
a semi quantitative analysis was performed for mucin expressing cells in the 
total tumor bearing population. We reviewed five to ten fields of each 
cancerous tissue at high magnification and counted the number of cells 
expressing diffuse and membranous type. The analysis graded as +++ if 50% to 
100% cancer cells stained positive for mucins, if  ++  if 10 % to 50% cancer 
cells stained positive and +  if less than 10% of cancer cells were stained 
positive for mucin staining. 
 +++ -   if 50% to 100% of cancer cells stained positive  
 ++   -   if 10 % to 50%  of cancer cells stained positive 
and   
 +     -  if less than 10% of cancer cells stained positive  
for mucin MUC-1 staining 
           Wang Zg et al 84(2012) studied 292 gastric cancer cases and found  no 
significant association between MUC1 expression with  age, gender, depth of 
invasion, lymph node metastasis and Lauren classification 
Reis, et al87 (2014) studied 55 cases of gastric carcinoma and found  
significant association between MUC1 expression with  lymphatic invasion 
and, nodal metastasis and no significant results with advanced stage. 
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           Utsunomiya, et al88 (2014) studied 139 cases of gastric carcinoma and   
found significant association between MUC1 expression with  lymphatic 
invasion, and  no significant results with nodal metastasis and advanced stage 
of the tumor. 
Kocer, et al89  (2014) studied 35 cases of gastric carcinoma and found 
significant results with MUC1 expression and Lauren’s histological 
classification of gastric carcinoma. 
 
IMMUNOHISTOCHEMISTRY 
In 1941, Albert coons et al was the first to label antibodies directly with 
fluorescent isocyanate. In 1960, Nakanae and Pierce et al, introduced indirect 
labeling technique, in which unlabelled antibody is followed by second 
antibody or substrate. Various stages of development of immunohistochemistry 
include Peroxidase- Antiperoxidase method (1970), Alkaline phosphatase 
labeling (1971), Avidin Biotin method (1977) and the two layer dextrin 
polymer technique (1993)69. 
 
ANTIGEN RETRIEVAL 
It can be done by the following different techniques to unmask the 
antigenic determinants of fixed tissue sections 
           1) Proteolytic enzyme digestion 
           2) Microwave Antigen retrieval 
           3) Pressure cookware antigen retrieval 
           4)Microwave and trypsin antigen retrieval 
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1) Proteolytic Enzyme Digestion 
In 1976, Huank et al introduced this technique to breakdown formalin 
cross linkages and to unmask the antigen determinants. Trypsin and 
proteinase70 were the most common used enzymes. Overdigestion, under 
digestion and antigen destruction are the disadvantages. 
 
2) Microwave Antigen Retrieval 
This is the most common used new technique in current practice. Micro 
oven heating involves boiling formalin fixed paraffin sections in various 
buffers for rapid and uniform heating .Antibodies against MUC1 work well 
after heat pretreatment in this method69. 
 
3) Pressure Cookware Antigen Retrieval 
In 1995, Miller et al compared and proved that pressure cooking method 
has fewer inconsistencies ,less time consuming and can be used to retrieve 
large numbers of slides than in microwave method71. 
 
PITFALLS OF HEAT PRETREATMENT 
Drying of sections at any stage after heat pretreatment destroys 
antigenicity. Nuclear details are damaged in poorly fixed tissues, while heating 
fibers and fatty tissue tend to detach from the slides. Not all antigens are 
retrieved by heat pretreatment. Also some antigens may show altered staging 
pattern. 
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DETECTION SYSTEMS 
After addition of specific antibodies to antigens, next step is to visualize 
the reaction complex of antigen antibody. The methods employed here are the 
direct and indirect. 
 
In the Direct method, primary antibody is directly conjugated with the 
label. Most commonly used labels are flourochrome, horse radish peroxidase 
(HRP) and alkaline phosphatase. 
 
And the indirect method is a two step method in which labeled 
secondary antibody reacts with primary antibody bound to specific antigen. 
The use of peroxidase enzyme complex or avidin biotin complex further 
increases the sensitivity of immunohistochemistry stains69.In 1993, Pluzek et 
al, introduced enhanced polymer one step staining ,in which large number of 
primary antibody and peroxidase enzymes are attached to dextran polymer 
backbone. This is the rapid and sensitive method72.                           
 
Dextran polymer conjugate ,two step visualization system is based on 
dextran technology in Epos system. This method has greater sensitivity and is 
less time consuming. 
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MATERIALS AND METHODS 
This study is both retrospective and prospective descriptive study of 
gastric adeno carcinomas conducted in the Institute of pathology,Madras 
medical college and Rajiv Gandhi Government General Hospital ,Chennai 
during the  period from June 2013 to June 2015. 
 
SOURCE OF DATA 
The gastric adenocarcinoma cases reported in gastrectomy specimens 
received in Institute of pathology, Madras Medical College,from the period of 
June 2013 to June 2015,from the Department of Surgery ,Department of 
Surgical Gastro Enterology, Government General hospital . 
 
INCLUSION CRITERIA 
All the gastric carcinoma cases reported in gastrectomy specimens 
irrespective of age, sex are included for the study. 
 
EXCLUSION CRITERIA 
 Non- neoplastic lesions and benign tumors of stomach  
 Gastric carcinomas reported in endoscopic biopsies 
 Gastrectomies performed for reasons other than carcinomas 
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METHOD OF DATA COLLECTION 
Detailed history of the cases regarding age, sex, history, type of 
procedure, history of neo adjuvant therapy, details of gross characteristics and 
nodal status were obtained for the gastrectomy cases reported during the period 
of study from Surgical pathology records. Hematoxylin and Eosin stained 4 µ 
thick sections of the paraffin tissue blocks of gastrectomy specimens were 
reviewed. The following clinical and pathological parameters were evaluated: 
Age, gender, tumor size, tumor location ( Eso -cardiac, body, antrum, 
pangastric), macroscopic appearance (Bormann Type I, Type II, Type III and 
Type IV). Carcinomas were classified as Intestinal and Diffuse based on the 
Lauren classification and into different histological types (tubular, papillary, 
mucinous, signet ring cell and diffuse). Regarding the depth of invasion, the 
carcinomas were classified into 4 groups: T1 (invasion of mucosa and 
submucosa), T2 (invasion of muscularis propria and subserosa), T3 ( invasion 
of serosa) and T4 (invasion of adjacent organs), and according to grade the 
carcinomas were divided into 3 groups: G1 (well differentiated), G2 
(moderately differentiated) and G3 (poorly differentiated) according to the 
recommendations of the American Joint Committee on Cancer (2002). Lymph 
node metastasis was assessed and the patients were divided into 3 groups: N0 
(No lymph node metastasis), N1 (metastasis in 1-6 nodes) and N2 (metastasis 
in 7 – 15 nodes). Carcinoma staging was done according to the standards of the 
American Joint Committee on Cancer (2002) and TNM classification of gastric 
carcinomas (Annexure –III). The tumors were further evaluated for the 
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presence of lymphocytic infiltration, perineural invasion and lympho-vascular 
invasion by tumor and were graded as present or absent. 50 cases of gastric 
adenocarcinomas of varying grades were randomly selected from the total 
cases and their representative formalin fixed paraffin embedded tissue samples 
were subjected to immunohistochemistry for marker MUC1,mucin. 
                                                                                               
IMMUNOHISTOCHEMICAL EVALUATION 
Immuohistochemical analysis of marker MUC1,mucin was done in 
paraffin embedded tissue samples using Super-sensitive polymer HRP system 
based on non-biotin polymeric technology. 4 µ thick sections from formalin 
fixed paraffin embedded tissue samples were transferred onto gelatin coated 
slides. Heat induced antigen retrieval was done. The antigen was bound with 
mouse monoclonal antibody (Biogenex) against MUC1, protein and then 
detected by the addition of secondary antibody conjugated with horse radish 
peroxidase-polymer and diaminobenzidine substrate. The step by step 
procedure of Immunohistochemistry is given in (Annexure IV). 
 
Antigen Vendor Species(clone) Dilution 
Positive 
control 
MUC1 BIOGENEX Mouse Ready to use Colon 
 
INTERPRETATION & SCORING SYSTEM:  
The immunohistochemically stained slides were analyzed for the 
presence of reaction, cellular localization, percentage of  cells stained and 
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intensity of reaction. Cytoplasmic / membrane staining was assessed for 
MUC1. To obtain a more precise relation between mucin and prognostic 
indicators, a semi quantitative analysis was performed  of mucin expressing 
cells ,reviewed five to 10 fields at high power magnification and  the analysis 
was graded as 
 
 +++ if 50–100% of cancer cells stained positive for mucins , 
 ++ if 10–50% cancer cells stained positive,   
  and  
 +if less than 10% of cancer cells were positive for mucin staining  
then the results were categorised into group 1(+), group 2 (++), or group 3 
(+++). 
     
STATISTICAL ANALYSIS   
The statistical analysis was performed using statistical package for 
social science software version 11.5 which consisted computing the frequency 
counts and percentages for qualitative variables and mean for the quantitative 
variables. The expression of MUC1 was correlated with clinic pathological 
factors like age, gender, tumor site, tumor configuration, size, Lauren’s type,  
histological types, histological grade, depth of infiltration, lymph node status, 
stage, lymphovascular invasion, perineural invasion, and  lymphocytic 
infiltration  using the Pearson’s Chi –Square test. The expression of MUC1 
were also correlated with each other  using the Mc Nemar’s test. T – test was 
used to detect the association between the mean MUC1 positive and negative 
groups. 
36 
 
 
OBSERVATION AND RESULTS 
 
                In the study period from June 2013 to June 2015, a total of 126 
gastrectomy specimens were received in the Institute of Pathology, Madras 
Medical College for histological examination, of these 126 gastrectomy 
specimens ,  124   were malignant,  2 were benign ulcers. In  this  total of 126  
gastrectomy specimens  ,124  were  reported as malignant tumors ,they  were 
120- gastric adeno carcinoma, 2-GIST,  2 NHL and  2  were done to treat  
bleeding benign ulcers. 
 
AGE AND SEX WISE DISTRIBUTION IN GASTRIC CARCINOMA 
 
Gastric cancers had a peak incidence in the age group of 51-60 years. In 
the current study, the youngest age of presentation of gastric cancer is 23 years 
and the maximum age is 84 and mean of  55 years. And the standard deviation 
is 12.5 (TABLE 1 ,CHART 1).  
 
           Among the 120 cases, 83 (69.2%) cases were reported in males and 37 
(30.2%) cases were reported in females (TABLE 2 AND CHART 2) 
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Table 1-Age Wise Distribution Of  Gastric Carcinoma 
Descriptive statistics 
 N Minimum Maximu
m 
Mean Std. 
Deviation 
Age 120 23.00 84.00 55.55 12.54628 
Age(years) Number of cases Percentage (%) 
 21-30 5 4.2 
31-40 12 10.0 
41-50 22 18.3 
51-60 38 31.7 
61-70 32 26.7 
Above 70 11 9.2 
Total 120 100% 
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Table 2- Gender Wise Distribution  In Gastric Carcinoma 
 
DISTRIBUTION OF SITE OF INVOLVEMENT OF GASTRIC 
CARCINOMA 
Among the 120 cases, 86 (71.7%) cases involved the pyloro-antrum, 
25(20.8%) involved the body, 3 (2.5%) involved the fundus , 5 (4.2%) involved 
the OG junction and 1 (0.8%) case was in cardia (Table 3 and Chart 3) 
Table 3- Distribution Of Site Of  Involvement  Of  Gastric Cancer 
Site of gastric cancer Number of cases Percentage 
 Pyloro-antrum 86 71.7% 
Body 25 20.8% 
Fundus 3 2.5% 
Og junction 5 4.2% 
Cardia 1 0.8% 
Total 120 100% 
 
  
Gender Number of cases Percentage   
 Male 83 69.2%   
Female 37 30.8%   
Total 120 100%   
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DISTRIBUTION OF GASTRIC CARCINOMA ACCORDING TO 
GROSS MORPHOLOGY 
Based on the gross morphology, the gastric tumors were divided into 4 
groups according to Bormann classification & the distribution is shown in 
(TABLE 4 AND CHART 4) 
Table 4- Distribution Of Gastric Carcinoma According To  
Gross Morphology 
 
DISTRIBUTION OF SIZE IN GASTRIC CARCINOMA 
Among the study samples, 56 cases (47%) had tumor less than 5 cm in 
size and 64 cases (53%%) were 5cm or more in size. (Table 5 & Chart 5) 
  
Gross Number of cases Percentage 
 Bormann type-I 19 15.8% 
Bormann type-II 36 30.0% 
Bormann type-III 49 40.8% 
Bormann type-IV 16 13.3% 
Total 120 100% 
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Table 5- Distribution  Of  Size In Gastric Carcinoma 
Size(cm) Number of cases Percentage 
>= 5.00 64 53% 
< 5.00 56 47% 
 
DISTRIBUTION OF HISTOLOGICAL SUBTYPES IN GASTRIC 
CARCINOMA 
The distribution of  histological type is shown in ( Table 6 & chart 6) 
Table 6-Distribution Of  Histological types In Gastric Cancers 
Histological types Number of cases Percentage 
 Tubular 77 64.2% 
Papillary 12 10.0% 
Diffuse 16 13.3% 
Signet ring 8 6.7% 
Mucinous 4 3.3% 
Lympho epithelial 
carcinoma 
1 0.8% 
Lymphoma 1 0.8% 
Squamous cell carcinoma 1 0.8% 
Total 120 100% 
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DISTRIBUTION OF GASTRIC CANCER ACCORDING TO LAUREN’S 
CLASSIFICATION 
120 of the gastric adenocarcinomas were grouped into 2 according to 
Lauren’s classification out of which 93 (79.5%) belonged to Intestinal type and 
24 (20.5%) belonged to Diffuse type  (Table 7 and Chart 7) 
Table 7- Distribution  Of  Gastric Carcinoma  According To  
Lauren’s Classification 
 
DISTRIBUTION OF HISTOLOGICAL GRADE IN GASTRIC 
CARCINOMA 
The gastric carcinomas were graded according to AJCC 
recommendation and were divided into 3 groups, out of which 16 cases 
(11.9%) were well differentiated (G1), 61 cases (51.7%) were moderately 
differentiated (G2) and cases 43 (36.4%) were in poorly differentiated (G3). 
(Table 8& Chart 8) 
 
 
 
Lauren’s type Number of cases Percentage 
 
Intestinal type 93 79.5% 
Diffuse type 27 20.5% 
Total 120 100% 
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Table 8- Distribution  Of Gastric Carcinoma According To  
Histological Grading 
 
DISTRIBUTION OF GASTRIC CANCER ACCORDING TO DEPTH OF 
INVASION 
In this study, 3 case (2.5%) showed invasion up to the sub mucosa (T1), 
29cases (26.8%) showed infiltration into the muscularis  propria or sub serosa 
(T2), 78cases (64.7%) showed infiltration into the serosa and 10 cases (6.0%) 
showed infiltration of adjacent organs (T4) (Table 9and Chart 9). 
Table 9- Distribution Of Gastric Carcinoma  According To Depth Of 
Invasion 
Depth of invasion Number of cases Percentage 
 T1 3 2.5% 
T2 29 26.8% 
T3 78 64.7% 
T4 10 6.0% 
Total 120 100% 
 
Grade Number of cases Percentage 
 G1 16 11.9% 
G2 61 51.7% 
G3 43 36.4% 
Total 120 100% 
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DISTRIBUTION OF LYMPH NODE METASTASIS IN GASTRIC 
CANCERS 
          This study showed that  62 cases (51.7%) had up to 6 nodes with 
metastatic carcinomatous deposit (N1),11 cases (9.2%) had 7 to 15 involved 
nodes (N2) while 47 cases (39.25%) had no node involvement (N0).(Table10 
&chart 10 ) 
Table 10 Distribution Of  Nodal  Metastasis In Gastric Cancer 
Lymph node status Number of cases Percentage 
 N0 47 39.2% 
N1 62 51.7% 
N2 11 9.2% 
Total 120 100% 
 
DISTRIBUTION OF GASTRIC CARCINOMAS ACCORDING TO 
STAGE 
          In the present study, 14 cases (10.9%) belonged to stage I, 40 cases 
(33.6%) belonged to stage II, 49cases (41.2%) belonged to stage III and 17 
cases (14.3%) belonged to stage IV. (Table 11 and Chart 11) 
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Table 11 Distribution Of Gastric Carcinomas According To Stage 
Stage Number of cases Percentage 
 IA 2 1.7% 
IB 12 9.2% 
II 40 33.6% 
.IIIA 41 34.5% 
IIIB 8 6.7% 
IV 17 14.3% 
Total 120 100% 
 
 
DISTRIBUTION OF OTHER PROGNOSTIC FACTORS IN GASTRIC 
CARCINOMA 
In this study, among the 120 cases, 51cases (42.5%) had  
lymphovascular invasion,12(10 %) cases had  perineural infiltration, 26(21.7%)  
cases had lymphocytic infiltration . (Table 12& Chart 12) 
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Table 12 –Distribution Of  Other Prognostic Factors In Gastric 
Carcinoma 
 
 
 
 
 
Lympho vascular 
invasion 
Number of cases Percentage 
 Absent 69 57.5% 
Present 51 42.5% 
Total 120 100% 
Peri neural 
infiltration 
Number of cases Percentage 
 Absent 108 90.0% 
Present 12 10.0% 
Total 120 100% 
Lymphocytic 
infiltration 
Number of cases Percentage 
 Absent 94 78.3% 
Present 26 21.7% 
Total 120 100% 
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RESULTS OF IMMUNOHISTOCHEMICAL STUDY IN  
GASTRIC CARCINOMA 
 
Of the total 120 cases, 50 cases of varying grades and stages of gastric 
adeno carcinomas were selected in a random manner and subjected to immune 
histochemical analysis with  the IHC marker MUC1. 
 
Distribution of Age and gender 
Of the 50 cases, there were  35 males (70%) and 15  females (30%). 
There were 16 cases (32%) below 50 years of age and 34 cases (68%) more 
than 50 years. (Table 13) 
Table 13 
 
 
 
 
 
 
 
Distribution of Location/site of involvement 
The tumor was located in the pyloroantrum in 35 cases (70%), body in 
11 cases (22%), fundus in  1 case(2%)  and in OG junction  3 cases(6%) . 
(Table 14) 
  
 Number of cases Percentage 
Age Less than 50 16 32.0% 
More than 50 34 68.0% 
Sex Male 35 70.0% 
Female 15 30.0% 
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Table 14 
 
 
 
 
 
 
 
Distribution of  Bormann gross type 
5 cases (10%) belonged to Bormann Type I, 18 cases (36%) belonged to 
Type II, 21 cases (42%) belonged to Type III and 6 cases (12%) belonged to 
type IV. (Table 15)  
Table 15 
 
 
 
 
 
 
 
 
Distribution of  Size 
The tumors ranged in size from 2 to 12 cm with an average of  5.42cm. 
There were 20 cases (40%) with tumor size <5 cm and 30 cases (60%) with 
size >5cm. (Table 16) 
  No.of cases Percentage 
Site Pyloroantrum 35 70.0% 
Body 11 22.0% 
Fundus 1 2.0% 
OG junction 3 6.0% 
BormannType No.of cases percentage 
I 5 10.0% 
II 18 36.0% 
III 21 42.0% 
IV 6 12.0% 
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Table16 
 
 
                
 
Distribution of Histological types 
38 cases (76%) were of the tubular type, 4 cases (8%) were of the 
papillary type, 6 cases (12%) were diffuse carcinomas, and 2 cases (4%) were 
of the mucinous type.  
 
Table17 
 
 
 
 
 
 
Distribution of Lauren’s type 
         45 cases (90%) belonged to Lauren’s Intestinal type and 5 cases (10%) 
belonged to the Diffuse type. (Table 18) 
  
Size No. of cases percentage 
<5cm 20 40.0% 
>5cm 30 60.0% 
Histological types No. of cases percentage 
Tubular 38 76.0% 
Papillary 4 8.0% 
Diffuse 6 12.0% 
Mucinous 2 4.0% 
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Table 18 
 
Distribution of Histological grading 
Among the 50 cases studied  7 (14%) cases were of G1, 25 (50%) cases 
were of G2 and 18 (36%) cases were of G3. (Table 19) 
 
Table 19 
 
 
 
 
 
Distribution  of  T stage.  
Table 20 
           
 
 
 
 
 8(16%) cases belonged to T2, 32 (64%) cases belonged to T3 and 10 
cases (20%) belonged to T4 (Table 20) 
Lauren’s type No.of cases percentage 
Intestinal 45 90.0% 
Diffuse 5 10.0% 
Grade No. of cases percentage 
G1 7 14.0% 
G2 25 50.0% 
G3 18 36.0% 
T stage No. of cases percentage 
T2 8 16.0 
T3 32 64.0 
T4 10 20.0 
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Distribution of N stage 
Nodal metastasis was present in 1-6 nodes (N1) in 23 cases (46%), 7-15 
nodes (N2) in 5 cases (10%) and absent in 22 (44%) cases. (Table 21a) 
  
Table 21a 
 
 
 
 
 
 
 
Distribution of other clinicopathological parameters 
Of the 50 cases, 20(40%) showed   lympho vascular invasion,  8 cases 
(16%) showed  perineural invasion, and 17   (34%) cases showed lymphocytic 
response. (Table 21b) 
Table 21b 
 
 N stage No. of cases Percentage 
Nodal status 
N0 22 44.0% 
N1 23 46.0% 
N2 5 10.0% 
  No .of cases Percentage 
Lymphovascular 
invasion 
Absent 30 60.0% 
Present 20 40.0% 
   
Perineural invasion Absent 42 84.0% 
Present 8 16.0% 
  
Lymphocytic 
infiltration 
Absent 33 66.0% 
Present 17 34.0% 
51 
 
Distribution of TNM staging in Gastric carcinoma 
6 (12%) cases belonged to stage I, 15 (30%) cases belonged to stage II, 
21 cases (42%) belonged to stage III and 8 cases (16%) belonged to stage IV.   
 
Table 22 
 
 
 
 
 
 
Distribution Of MUC1 In Gastric Carcinoma 
In this study ,of  the  total 50 cases, 9cases (18%) expressed (3+) 
positive reaction for MUC1, 6 cases (12%)  expressed  (2+) positive reaction 
for MUC1 ,17 cases (34%) expressed  (1+)  positive  reaction for MUC1 and  
18 cases (36%) were negative for MUC1 (Table 23 & Chart 13) 
 
Table 23 – Distribution Of MUC1 In Gastric Carcinoma 
 
 
 
 
Stage No. of cases Percentage 
I 6 12.0% 
II 15 30.0% 
III 21 42.0% 
IV 8 16.0% 
Marker Grading Number of cases Percentage 
MUC1 
1+ 17 34.0% 
2+ 6 12.0% 
3+ 9 18..0% 
Negative 18 36.0% 
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CORRELATION OF MUC1 WITH VARIOUS CLINICO 
PATHOLOGICAL FACTORS 
MUC1 positivity  among  patients below 50 years, 3+  was noted in 
37.5% of cases, 2+ in 14.3% cases, 1+ in 35.3% of cases and in patients above 
50 years 62.5% of cases were 3+ , 85.7%  were 2+ and 66.7% were 1+. 33.3% 
of cases below 50 years of age and 66.7% of cases above 50 years show 
negativity for MUC1 (Table 24 & Chart 14) 
 
Table 24 Correlation Of  Age With MUC1Expression 
               In years 
MUC1 
Total Negat
ive 
1+ 2+ 3+ 
Age_ 
group 
Less than 
50 
Count 6 6 1 3 16 
MUC1(%) 33.3% 35.3% 14.3% 37.5% 32.0% 
More than 
50 
Count 12 11 6 5 34 
 MUC1(%) 66.7% 64.7% 85.7% 62.5% 68.0% 
Total 
Count 18 17 7 8 50 
MUC1(%) 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
 
Pearson Chi-Square  1.220    p>0.05 (0.748) 
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CORRELATION OF GENDER WITH MUC1 EXPRESSION 
          MUC1  positivity was found as 3+ in 62.5%, ,2+ in 85.7% and 1 + in 
70.6% of males ,with 66.7%  of males showed negativity and in females 3+ in 
37.5%, 2+ in 14.3% and 1+ in 29.4% of females ,with 33.3% of females  
showed negativity and  a slight predominance in  positivity among male 
population was seen . (Table 25  & Chart 15)  
 
Table 25 Correlation Of  Gender With MUC 1 Expression 
 
MUC1 
Total 
Negative 1+ 2+ 3+ 
Sex 
Male 
Number of 
cases 
12 12 6 5 35 
MUC1 (%) 66.7% 
70.6
% 
85.7% 62.5% 70.0% 
female 
Number of 
cases 
6 5 1 3 15 
 MUC1 (%) 33.3% 
29.4
% 
14.3% 37.5% 30.0% 
Total 
Count 18 17 7 8 50 
% within 
MUC1 
100 100 100 100 100 
Pearson Chi-Square 1.135 p>0.05 (0.769) 
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CORRELATION OF TUMOUR SITE WITH MUC1 EXPRESSION 
 
In the present study, MUC1 expression of  3+ was found  in 75.%,  2+ in 
57.1%, 1+ in 64.7% of tumors in the pyloro antrum, 3+ in 12.5%, 2+ in 28.6% 
and  1+ in 29.4% of tumors in the body, 3+ in 12.5% of tumors in the fundus, 
and 2+ in 14.3% ,1+ in 5.9% of tumors in OG junction . The association with 
respect to site was found to be significant with increased expression of  MUC1 
seen in the tumors located in the pyloro - antrum  (Table 26 and Chart16)  
 
Table 26 Correlation Of Tumor Site With MUC 1 Expression 
 
 
MUC1 
Total Nega
tive 1+ 2+ 3+ 
site Pyloroan
trum 
Number of 
cases 
14 11 4 6 35 
MUC1 (%) 77.8
% 
64.7% 57.1% 75.0% 70.0% 
Body Number of 
cases 
3 5 2 1 11 
MUC1(%) 16.7
% 
29.4% 28.6% 12.5% 22.0% 
Fundus Number of 
cases 
0 0 0 1 1 
MUC1(%) 0.0% 0.0% 0.0% 12.5% 2.0% 
OG 
junction 
Number of 
cases 
1 1 1 0 3 
 MUC1(%) 5.6% 5.9% 14.3% 0.0% 6.0% 
Total Number of 
cases 
18 17 7 8 50 
MUC1(%) 100 100 100 100 100 
          Pearson Chi-Square 8.078 p>0.05 (0.526) 
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 CORRELATION OF GROSS TYPE WITH MUC1 EXPRESSION 
 
           Among the various gross types, MUC 1 positivity 3+ was noted in 3 
cases (37.5%) of Bormann type I, 1 case (12.5%) of Bormann type II,  3 cases 
(37.5%) of Bormann type III and 1 case (12.5%) of Bormann type IV. (Table 
27 and Chart17) 
 
Table 27-Correlation Of Gross Type With MUC1 Expression 
 
Pearson Chi-Square 19.138* p<0.05 (0.24) 
 
 
 
 
 
MUC1 
Total Negati
ve 
1+ 2+ 3+ 
Gross 
TYPE 
I 
Number of 
cases 
1 1 0 3 5 
MUC1(%) 5.6% 5.9% 0.0% 37.5% 10.0% 
TYPEI
I 
Number of 
cases 
4 7 6 1 18 
MUC1(%) 22.2% 41.2% 85.7% 12.5% 36.0% 
TYPE 
III 
Number of 
cases 
9 8 1 3 21 
MUC1(%) 50.0% 47.1% 14.3% 37.5% 42.0% 
TYPE 
IV 
Number of 
cases 
4 1 0 1 6 
MUC1(%) 22.2% 5.9% 0.0% 12.5% 12.0% 
Total Number of 
cases 
18 17 7 8 50 
MUC1(%) 100 100 100 100 100 
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CORRELATION OF TUMOUR SIZE WITH MUC1 EXPRESSION 
          In the present study, MUC1 positivity 3+ was noted in an increased 
frequency (87.5%) in cases with tumor size >5cm compared to the 12.5% of 
cases with size <5cm. (Table 28 and Chart 18)  
Table 28 Correlation Of Tumor Size With MUC1 Expression 
 
MUC1 
Total Negati
ve 
1+ 2+ 3+ 
size 
<5cm 
Count 6 9 4 1 20 
MUC1 (%) 33.3% 52.9% 57.1% 12.5% 40.0% 
>5cm 
Count 12 8 3 7 30 
MUC1(%) 66.7% 47.1% 42.9% 87.5% 60.0% 
Total 
Count 18 17 7 8 50 
MUC1(%) 100 100 100 100 100 
Pearson Chi-Square 4.898 p>0.05 (0.179) 
 
CORRELATION OF HISTOLOGICAL TYPE WITH MUC1 
Among histological forms, 50% of tubular carcinomas, 12.5% of 
papillary carcinoma, 37.5% of diffuse carcinomas and 66.7% of diffuse 
carcinomas showed   3+ positivity for MUC1. 85% of tubular carcinomas, 
14.3% of papillary carcinomas showed 2 + positivity for MUC1. 76.5% of 
tubular carcinomas, 11.8% of papillary carcinoma, 5.9 % of Diffuse 
carcinomas and 5.9% of  mucinous  carcinomas showed 1+ positivity for 
MUC1. 83.3%  of tubular carcinomas, 11.1% of papillary carcinoma, 0% of 
Diffuse carcinomas and 5.6% of mucinous carcinomas showed negativity for 
MUC1. (Table 29and Chart 19) 
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Table 29 Correlation Of Histological Type With MUC1 
 MUC1 
Total Negat
ive 
1+ 2+ 
3+ 
Histologic
al_type 
Tubul
ar 
Number of 
cases 
15 13 6 4 38 
MUC1(%) 83.3% 76.5% 85.7% 50.0% 76.0% 
Papill
ary 
Number of 
cases 
0 2 1 1 4 
MUC1(%) 0.0% 11.8% 14.3% 12.5% 8.0% 
Diffus
e 
Number of 
cases 
2 1 0 3 6 
MUC1(%) 11.1% 5.9% 0.0% 37.5% 12.0% 
Mucin
ous 
Number of 
cases 
1 1 0 0 2 
MUC1 (%) 5.6% 5.9% 0.0% 0.0% 4.0% 
Total 
Number of 
cases 
18 17 7 8 50 
MUC1(%) 100 100 100 100 100 
Pearson Chi-Square 9.792 p>0.05 (0.368) 
 
CORRELATION OF LAUREN’S CLASSIFICATION WITH MUC1 
EXPRESSION  
 When Lauren’s classification was taken into account, a greater 
frequency of MUC1 expression 3+ was seen with 62.5% ,2+ in 100% , 1+ in 
94.1% of  Intestinal type cancers in comparison with  3+ in 37.5%, 2+ in 0%, 
1+ in 5.9%  of diffuse type carcinomas  (Table 30 and Chart 20) 
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Table 30 - Correlation Of   Lauren’s  Classification With  
MUC1 Expression 
 
 
MUC1 
Total Negat
ive 1+ 2+ 3+ 
Lauren 
Intestinal 
type 
Number of 
cases 
17 16 7 5 45 
MUC1 (%) 94.4% 94.1% 100.0% 62.5% 90.0% 
Diffuse type 
Number of 
cases 
1 1 0 3 5 
MUC1 (%) 5.6% 5.9% 0.0% 37.5% 10.0% 
Total 
Number of 
cases 
18 17 7 8 50 
MUC1 (%) 100 100 100 100 100 
 
Pearson Chi-Square 8.215* p<0.05 (0.042) 
 
 
CORRELATION OF TUMOUR GRADE WITH MUC1 EXPRESSION 
An increasing percentage of cases showing MUC1 3+ Positivity with 
increasing tumor grade was observed. 1 2.5% of moderately differentiated 
tumors (G2) and 87.5% of poorly differentiated tumors (G3) showing 3+ 
positivity for MUC1 was observed.  0% of well differentiated tumors showed 
MUC1 3+ positivity (Table 31 and Chart 21) 
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Table 31 Correlation  Of  Tumor Grade With MUC1 Expression 
 
Pearson Chi-Square  17.965  p *<0.05 (0.048) 
 
CORRELATION OF T STAGE WITH MUC1 EXPRESSION 
          According to the T stage, 0% of T2 cases, 62.5% of T3 cases and 37.5% 
of T4 cases showing  3+ positivity for MUC1 was noted. (Table 32 and Chart 
22) 
 
 
 
MUC1 
Total 
Negative 1+ 2+ 3+ 
Grade 
1 
Number of 
cases 
6 1 0 0 7 
MUC1(%) 33.33% 5.88% 0.00% 0.00% 14.00% 
2 
Number of 
cases 
10 9 5 1 25 
MUC1(%) 55.56% 52.94% 71.43% 12.50% 50.00% 
3 
Number of 
cases 
2 7 2 7 18 
MUC1(%) 11.11% 41.18% 28.57% 87.50% 36.00% 
Total 
Number of 
cases 
18 17 7 8 50 
MUC1(%) 100 100 100 100 100 
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Table 32 Correlation  Of  T Stage With MUC1 Expression 
 
MUC1 Total Negative 1+ 2+ 3+ 
Dep
th 
T2 
Number of 
cases 
6 2 0 0 8 
MUC1(%) 33.3% 11.8% 0.0% 0.0% 16.0% 
T3 
Number of 
cases 
11 11 5 5 32 
MUC1(%) 61.1% 64.7% 71.4% 62.5% 64.0% 
T4 
Number of 
cases 
1 4 2 3 10 
MUC1(%) 5.6% 23.5% 28.6% 37.5% 20.0% 
Total 
Number of 
cases 
18 17 7 8 50 
MUC1(%) 100 100 100 100 100 
 
Pearson Chi-Square  9.524  p>0.05 (0.146) 
 
CORRELATION OF N STAGE WITH MUC 1EXPRESSION 
          In this study,12. 5% of   N0 cases, 62.5%  of  N1 cases and 25%  of N2 
Cases show MUC1 3+ positivity.. (Table 33 and chart 23) 
Table 33 Correlation Of  N Stage With  MUC 1 Expression 
 MUC1 Total 
- 1+ 2+ 3+ 
LN N0 Number of cases 9 8 4 1 22 
MUC1(%) 50.0% 47.1% 57.1% 12.5% 44.0% 
N1 Number of cases 8 8 2 5 23 
MUC1(%) 44.4% 47.1% 28.6% 62.5% 46.0% 
N2 Number of cases 1 1 1 2 5 
MUC1(%) 5.6% 5.9% 14.3% 25.0% 10.0% 
Total Number of cases 18 17 7 8 50 
MUC1(%) 100 100 100 100 100 
 
Pearson Chi-Square 5.784   p>0.05 (0.448) 
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CORRELATION  OF TNM  STAGE  WITH  MUC1 EXPRESSION 
          MUC1 positivity 3+ was noticed in 0% of stage I cases,12.5% of stage II  
 
Table 34 -Correlation Of  TNM  Stage With MUC1 Expression 
 MUC1 Total 
Negat
ive 
1+ 2+ 3+ 
sta
ge 
IB Number of 
cases 
4 2 0 0 6 
MUC1(%) 22.2% 11.8% 0.0% 0.0% 12.0% 
II Number of 
cases 
6 5 3 1 15 
MUC1(%) 33.3% 29.4% 42.9% 12.5% 30.0% 
III
A 
Number of 
cases 
7 6 2 2 17 
MUC1(%) 38.9% 35.3% 28.6% 25.0% 34.0% 
III
B 
Number of 
cases 
0 1 1 2 4 
MUC1(%) 0.0% 5.9% 14.3% 25.0% 8.0% 
IV Number of 
cases 
1 3 1 3 8 
MUC1(%) 5.6% 17.6% 14.3% 37.5% 16.0% 
Total Number of 
cases 
18 17 7 8 50 
MUC1(%) 100 100 100 100 100 
 
Pearson Chi-Square 13.377  p>0.05 (0.342) 
  
cases,50% of stage III cases  and  37.5%  of stage IV cases.2+ in 0% of stage I 
cases,42.9% of stage II cases,42.9% of stage III cases  and  14.3%  of stage IV 
cases. 1+ in 11.8% of stage I cases, 29.4% of stage II cases,41.2% of stage III 
cases  and  17.6 %  of stage IV cases (Table 34 and Chart 24) 
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CORRELATION OF MUC1 WITH OTHER PROGNOSTIC 
PARAMETERS  
               In this study, MUC1 3+ Positivity was observed in 25% of cases with 
lymphovascular invasion, 25% of cases with perineural invasion and 12.5% of 
cases having lymphocytic infiltration. (Table 35 & chart 25)                                                                 
Table 35- Correlation Of  MUC1 With  Other Prognostic Parameters 
 MUC1 
Total Neg
ativ
e 
1+ 2+ 3+ 
Lympho 
vascular 
invasion 
Abse
nt 
Number of cases 13 8 3 6 30 
MUC1(%) 72.2
% 
47.1
% 
42.9
% 
75.0
% 
60.0
% 
Prese
nt 
Number of cases 5 9 4 2 20 
MUC1(%) 27.8
% 
52.9
% 
57.1
% 
25.0
% 
40.0
% 
Total Number of cases 18 17 7 8 50 
Perineur
al 
invasion 
Absent Number of cases 16 13 7 6 42 
MUC1(%) 88.9
% 
76.5
% 
100.
0% 
75.0
% 
84.0
% 
Present Number of cases 2 4 0 2 8 
MUC1(%) 11.1
% 
23.5
% 
0.0% 25.0
% 
16.0
% 
Total Number of cases 18 17 7 8 50 
Lympho
cytic 
infiltrati
on 
Absent Number of cases 12 9 5 7 33 
MUC1(%) 66.7
% 
52.9
% 
71.4
% 
87.5
% 
66.0
% 
Present Number of cases 6 8 2 1 17 
MUC1(%) 33.3
% 
47.1
% 
28.6
% 
12.5
% 
34.0
% 
Total Number of cases 18 17 7 8 50 
 
63 
 
 
The present study showed that there was statistically significant 
association between MUC1 expression and Bormann gross typing and Lauren’s 
histological typing and Histological tumor grading. MUC1  positive expression 
was seen to increase with increasing age and intestinal type of gastric 
adenocarcinomas.  
 
But when subjected to statistical analysis this association was not found 
to be significant with age. Increased MUC1 expression was noted in Bormann 
type III and type IV tumor. 
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DISCUSSION 
          Gastric cancer is a life threatening disease and represents a significant 
health problem worldwide. It is the second most common cancer worldwide 
and the third most common cancer in India73. The incidence of gastric cancer in 
Chennai is about 13.6 per lakh in men and 6.5 per lakh in women20 
          Many biological markers have been examined as possible tools for the 
evaluation of the biological behavior of gastric cancer in order to predict the 
clinical outcome. Among these, immunohistochemical staining of MUC1 have 
been proposed to be of significant value. 
          In the present study, immunohistochemical evaluation was done in 50 
cases of gastric carcinomas and an attempt was made to correlate the MUC1 
expression with the known prognostic factors of gastric cancers.  
          This study showed the age of gastric cancer patients ranged from 20 
years to 78 years with the mean age of 55 years. The highest incidence of 
gastric cancer occurred in 51 to 60 year age group. This is in concurrence with 
the  study done by Y.E. Joo et al who observed a mean age of 58.7 years with a 
range from 28 to 79 years.  In the study done by Nobuyuki Igarashi et al the 
incidence of gastric cancer in men and women was 74.1% and 25.9% 
respectively.  
In concurrence with the above studies, a significant predominance of 
gastric cancers was found in men accounting for 70% of the cases and women 
accounting  for 30% was observed. 
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Site    
        The most common site of gastric cancer in this study is the pyloro – 
antrum (54%). This is almost similar to the study of N.E. Tzanakis et al102 and 
Daniela Lazar et al75. In their study, Tzanakis et al74 observed 51.6% tumours 
in the antrum and Daniela Lazar et al75 observed 50.8% tumours in the antrum 
(Table 36). 
TABLE 36 – COMPARISON OF DISTRIBUTION OF GASTRIC 
TUMOUR LOCATION 
Tumour 
location 
N.E.Tza
nakis et 
al74 
Daniela 
Lazar et 
al75 
Czyzewska 
J et al79 
Current 
study 
Antrum 51.6% 50.8% 60% 70% 
Body 34.4% 24.5% 20% 22% 
Fundus 14% 13.1% 15.6% 2% 
OG junction - 11.4% 4.4% 6% 
 
Bormann type 
          Daniela Lazar et al75 observed 8.2% of Bormann type I tumors, 32.7% of 
type II tumors, 36% of type III tumors and 14.7% of type IV tumors. Jurgen et 
al76 observed 20% of type I tumors, 40% of type II tumors, 28% of type III 
tumors and 12% of type IV tumors. Similar findings were also observed by 
Jurgen et al76. In the current study 10% of  Bormann type I, 36 % of  Bormann 
type II, 42% of  Bormann type III and 12% of  Bormann type IV (table 37). 
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Table 37 
Tumour location 
Daniela Lazar 
et al75 
Jurgen et al76 Current study 
Type I 8.2% 20% 10% 
TypeII 32.7% 40% 36% 
Type III 36% 28% 42% 
Type IV 14.7% 12% 12% 
 
Size 
        In this study, an average tumor size of 5 cm was observed which was 
similar to the findings observed by Y.E.Joo77 et al and Tzanakis et al74. Y.E Joo 
et al observed an average tumour size of 5.2 cm and Tzanakis et al74 observed 
an average tumour size of 5.1 cm (table 38).  
Table 38 
Tumor size Y.E.Joo et al77 Tzanakis et al74 
Current 
study 
In cm 5.2 5.1 5 
 
Histological subtype 
The most common histological subtype of gastric cancer in this study is 
Tubular carcinoma. This is almost similar to the study of Daniela Lazar et al75 
and Y.Kakeji et al78 (Table 39).  
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TABLE 39 – COMPARISON OF DISTRIBUTION OF HISTOLOGICAL 
TYPES OF GASTRIC CARCINOMA 
Histological type Daniela et al75 Y.Kakeji et al78 Current study 
Tubular carcinoma 45.9% 89.5% 76% 
Papillary carcinoma 8.2% 2% 8% 
Diffuse carcinoma 4.9% - 12% 
Mucinous 
carcinoma 
27.8% 3.1% 4% 
 
Lauren’s histological type 
The most common histological type (Lauren’s) in this study was the 
Intestinal type (82%). This is similar to observations made by Casasola et al106 
wherein, intestinal type accounted for 81.9% and diffuse type accounted for 
18.1% (Table 40).   
 
TABLE 40– COMPARISON OF LAUREN’S HISTOLOGICAL TYPE 
Lauren’s 
type 
Czyzewska 
et al79 
Daniela et 
al75 
Casasola et 
al80 
Current 
study 
Intestinal 
type 
75.5% 72.1% 81.9% 90% 
Diffuse type 24.5% 27.9% 18.1% 10% 
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Histological Grading 
In the present study, the G2 (moderately differentiated) tumors were 
more common than the other grades of distribution. This was in concurrence 
with the study conducted by Casasola et al80 (Table 41).  
 
 
TABLE 41 – COMPARISON OF GRADE OF TUMOUR 
Grade 
Casasola et 
al80 
Tzanakis et 
al74 
Daniela et 
al75 
Current 
study 
G1 16% 5.4% 3.2% 14% 
G2 74.6% 22.6% 32.8% 50% 
G3 9.4% 69.9% 64% 36% 
 
 
Depth of tumor               
A higher proportion of T3 tumors, closely followed by T2 tumors were 
observed in this study, similar to the studies of Giovanni de Manzoni et al81, 
and Y.E. Joo77 et al (Table 42).  
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TABLE –42 COMPARISON OF DEPTH OF TUMOUR 
 
Depth T1 T2 T3 T4 
Giovanni et al81 - 25% 66% 9% 
Y.E.Joo et al77 13.4% 24.3% 51.2% 11.1% 
Daniela et al75 6.5% 14.7% 27.8% 49.2% 
Jurgen et al76 16.9% 36.6% 38.6% 7.9% 
Current study - 16% 64% 20% 
 
Nodal status 
There was nodal metastasis in 56% of the cases and no nodal metastasis 
in 44% of cases. This was similar to the study by Y.E Joo et al 77who (table 43) 
 
TABLE 43 – COMPARISON OF NODAL METASTASIS 
 
 
 
 
 
 
observed nodal metastasis in 51.3% cases and no nodal metastasis in 
48.7% cases & the study by Czyzewska J et al 79who observed nodal metastasis 
in 55.6% and no nodal metastasis in 44.4% (Table 44) 
 
Nodal status N0 N1 N2 
Giovanni et al81 21.4% 35.7% 42.9% 
Daniela et al75 29.5% 26.2% 37.8% 
Jurgen et al76 32.4% 22% 45.6% 
Current study 44% 46% 10% 
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TNM Stage 
Most of the cases presented in stage III followed closely by  stage II in 
this study. This did not concur with the other studies which showed a 
predominance of stage IV tumors (Table 44)  
 
TABLE 44 COMPARISON OF STAGE OF GASTRIC TUMOUR 
Stage Daniela et al75 Y.E. Joo et al77 Jurgen et al76 
Current 
study 
I 13.1% 34.4% 27.2% 12% 
II 11.4% 16% 13.9% 30% 
III 31.1% 31.1% 28.1% 42% 
IV 42.6% 18.5% 30.8% 16% 
 
Other parameters        
40% cases had lymphovascular invasion which was not similar to the 
observation made by Daniela Lazar et al75, who reported 62.3% and Ji Yoon 
Choi et al82 who reported 79.35% cases with  invasion in his study.There were 
lymphocytic infiltration in 36% and perineural infiltration in 16% of gastric 
carcinoma cases. This observation is parallel to the 31.7% perineural 
infiltration reported in the study conducted by Luo Tianhang et al 83. 
 
The expression of  MUC1 was noted as 1+,2+,3+ and _ among, 
34%,14%,16% and 36%  of  cases respectively. This proportion is comparable 
with the other studies conducted by Wang Zg et al84  in the Japanese 
71 
 
population, Iihan et al , Nguyen et al and these  studies show MUC1 expression 
ranging from 24% to 90%. This fluctuation could be due to different 
methodologies used and to varying characteristics of the studied cases (Table 
45).  
 
TABLE 45 - COMPARISON OF MUC1 EXPRESSION WITH OTHER 
STUDIES 
 
 
 
 
 
 
 
           Wang Zg et al 84(2012) studied 292 gastric cancer cases and found  no 
significant association between MUC1 expression with  age, gender, depth of 
invasion, lymph node metastasis and Lauren classification. 
 
Similar to the study of  Wang Zg et al 84,current study also show no 
significant association between MUC1 and the age, gender, depth of invasion, 
lymphnode metastasis. 
 
            And in contradictory to the study of Wang Zg et al 84 ,the present study 
show significant association between MUC1 expression and Lauren’s 
histological type of gastric carcinomas. 
Studies MUC1 positive MUC1 Negative 
Wang Zg et al84 42% 58% 
IIhan et al85 90% NA 
Nguyen et al86 24% 76% 
Current study 64% 36% 
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Reis, et al87 (2014) studied 55 cases of gastric carcinoma and found  
significant association between MUC1 expression with  lymphatic invasion 
and, nodal metastasis and no significant results with advanced stage. 
 
            And  In contradictory to the study of  Reis, et al87 ,the present study 
show  no significant association between MUC1 expression and lymphatic 
invasion and, nodal metastasis and no significant results with advanced stage. 
 
Utsunomiya, et al88 (2014) studied 139 cases of gastric carcinoma and   
found significant association between MUC1 expression with  lymphatic 
invasion, and  no significant results with nodal metastasis and advanced stage 
of the tumor. 
 
The present study correlated with the study of Utsunomiya, et al 88   in 
which there was no significant results with nodal metastasis and stage of the 
tumor with the MUC1 expression. 
 
            Kocer  et al89 (2014) studied 35 cases of gastric carcinoma and found 
significant results with MUC1 expression and Lauren’s histological 
classification of gastric carcinoma. 
 
The present study correlated with the study of   Kocer, et al89  in which 
there was  significant results with MUC1 expression and Lauren’s histological 
classification of gastric carcinoma. 
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SUMMARY 
 
• Gastric cancers had a peak incidence in the age group of 51 – 60 years, 
with the mean age of 55.5 years.  
• 70% cases of gastric cancer were reported in males and 30% in females.  
• The most common location of gastric cancer was at the pyloro - antrum 
which constituted about 71.7% of the cases.  
• 53% of tumors were more than or equal to 5 cm.  
• The most common histological type was tubular carcinoma which 
accounted for 64.2%of cases.  
• The most common Lauren’s histological subtype was Intestinal 
carcinoma which accounted for 79.5% of cases.  
• G2 (moderately differentiated grade) was the most common grade 
accounting for 51.7 % of cases.  
• 64.7 % of cases presented in T3 (invasion into the serosa) stage.  
• Nodal metastasis was observed in 61.1% of cases.  
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• Most of the tumours (41.2%) presented in stage III.  
• Lymphovascular invasion was seen in 42.5% of cases. 
• Perineural infiltration was seen in 10% of cases.  
• Lymphocytic response was seen in 21.7% of cases  
• MUC 1 expression was seen in 64% of cases. 1+ in 34%, 2+ in 14% and   
3+ in 16% of cases 
• An increase in MUC1 (3+) positivity expression was seen with 
increasing age and intestinal type of gastric adenocarcinoma. 
• MUC1 expression showed statistically significant association with 
tumor gross Bormann typing , Laurens histological Classification and 
Histological grading of the tumor. 
• No statistically significant association between MUC1 expression and 
age, gender, tumor size, depth, stage, vascular invasion, perineural 
infiltration and  lymphocytic infiltration was found. 
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CONCLUSION 
 
The incidence of gastric carcinoma was higher in this study group than 
the western population. Many patients presented in older age with 
predominance in males. MUC1 expression was found in 64% of cases which is 
similar to that of western population. MUC1 expression was significantly 
associated with Bormann gross typing, Lauren’s histological classification and 
grading of the tumor. MUC1 mucin , positivity was seen to increase with 
increasing age, nodal stage and TNM stage. But when subjected to statistical 
analysis this association was not found to be significant. There was a slight 
predominance in males when compared to females and intestinal type tumors 
than diffuse type gastric carcinomas 
    
To conclude, the role played by MUC1 marker in the aggressiveness of 
gastric carcinoma is complex and still not clarified. However, identifying the 
expression of   MUC1 in gastric carcinoma could be helpful to identify a group 
of patients at high risk and poor survival. A larger sample size and in 
concordance with other proliferation markers and  close follow up of these 
patients for 5  or more years could be helpful in utilizing MUC1 as an aid in 
long term prognosis and therapeutic approach of the high risk patients. 
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ANNEXURE – I 
 
PROFORMA  
Case number :                                                                                     Name :  
HPE number :                                                                                        Age :  
IP number :                                                                                            Sex :  
Clinical history :  
Risk factors, if any :  
Clinical diagnosis :  
Imaging :  
Endoscopy :  
Previous HPE report:  
Nature of specimen : Total gastrectomy/Subtotal gastrectomy/Others  
GROSS  
Proximal circumference :                                                    Greater curvature:  
Distal circumference :                                                          Lesser curvature :  
Tumour site :  
Tumour size :  
Tumour configuration :                                                        Depth of invasion:  
Margins : Proximal :                                                            Distal :  
Associated findings :  
Total nodes dissected :  
MICROSCOPY  
Histological type 
Histological grade : G1 / G2 / G4 / G4  
Depth of invasion :  
Margins : Proximal : Free / Involved  
Distal : Free / Involved  
Lymphatic invasion : Present / Absent  
Venous invasion : Present / Absent  
Perineural invasion : Present / Absent  
Lymphocytic response : Present / Absent  
Necrosis : Present / Absent  
Associated findings:  
Total number of nodes dissected: Number of nodes involved:  
Distant metastasis :  
TNM staging :  
IMMUNOHISTOCHEMISTRY  
MUC1  score : 
% of tumour nuclei showing reaction 
 
                                          
 
 
 
 
 
 
 
 
 
 
ANNEXURE II 
  
TNM  STAGING  OF GASTRIC TUMOURS  
 
T – Primary Tumour  
 
TX - Primary tumour cannot be assessed  
T0 - No evidence of primary tumour  
Tis - Carcinoma in situ  
T1 - Tumour invades lamina propria or submucosa  
T2 - Tumour invades muscularis propria or subserosa  
T3 - Tumour penetrates serosa without invasion of adjacent structures  
T4 - Tumour invades adjacent structures  
 
N – Regional Lymph Nodes  
 
NX - Regional lymph nodes cannot be assessed  
N0 - No regional lymph node metastasis  
N1 - Metastasis in 1 to 6 regional lymph nodes  
N2 - Metastasis in 7 to 15 regional lymph nodes  
N3 - Metastasis in more than 15 regional lymph nodes  
 
M – Distant Metastasis  
 
MX - Distant metastasis cannot be assessed  
M0 - No distant metastasis  
M1 - Distant metastasis  
 
STAGE GROUPING  
 
Stage 0                   Tis             N0           M0  
Stage IA                 T1              N0           M0  
Stage IB                 T1              N1          M0  
                               T2              N0          M0  
Stage II                   T1              N2          M0  
                                T2              N1          M0  
                                T3              N0          M0  
 
Stage IIIA               T2              N2          M0  
                                T3              N1          M0  
                                T4              N0          M0  
Stage IIIB               T3               N2          M0  
 
Stage IV                  T4        N1, N2, N3    M0  
                           T1, T2, T3       N3           M0    
                              Any T    Any N          
ANNEXURE - III 
 
 
WHO CLASSIFICATION OF GASTRIC TUMORS  
  
EPITHELIAL TUMORS  
Intraepithelial neoplasia – Adenoma  
 
CARCINOMA  
Adenocarcinoma  
Intestinal type  
Diffuse type  
Papillary adenocarcinoma  
Tubular adenocarcinoma  
Mucinous adenocarcinoma  
Signet-ring cell carcinoma  
Adenosquamous carcinoma  
Squamous cell carcinoma  
Small cell carcinoma  
Undifferentiated carcinoma  
Others  
Carcinoid (well differentiated endocrine neoplasm)  
 
NON-EPITHELIAL TUMORS 
Leiomyoma  
Schwannoma  
Granular cell tumor  
Glomus tumor  
Leiomyosarcoma  
Gastro Intestinal  stromal tumor  
Benign  
Uncertain malignant potential  
Malignant  
Kaposi sarcoma  
Others  
Malignant lymphomas  
Marginal zone B-cell lymphoma of MALT-type  
Mantle cell lymphoma  
Diffuse large B-cell lymphoma  
Others  
  
SECONDARY TUMORS 
 
 
 
ANNEXURE IV 
 
IMMUNOHISTOCHEMISTRY PROCEDURE 
 
1. 4µ thick sections were cut from formalin fixed paraffin embedded tissue  
     samples and transferred to gelatin-chrome alum coated slides.  
2. The slides were incubated at 58ºC for overnight.  
3. The sections were deparaffinized in xylene for 15 minutes x 2 changes.  
4. The sections were dehydrated with absolute alcohol for 5 minutes x 2  
    changes.  
5. The sections were washed in tap water for 10 minutes.  
6. The slides were then immersed in distilled water for 5 minutes.  
7. Heat induced antigen retrieval was done with microwave oven in appropriate  
     temperature with appropriate buffer for 20 to 25 minutes.  
8. The slides were then cooled to room temperature and washed in running tap  
     water for 5 minutes.  
9. The slides were then rinsed in distilled water for 5 minutes.  
10. Wash with appropriate wash buffer (citrate buffer) for 5 minutes x 2  
      changes.  
11. Apply peroxidase block over the sections for 10 minutes.  
12. Wash the slides in citrate buffer for 5 minutes x 2 changes.  
13. Cover the sections with power block for 15 minutes.  
14. The sections were drained (without washing) and appropriate primary  
      antibody was applied over the sections and incubated for 1 hour  
15. The slides were washed in citrate buffer for 5 minutes x 2 changes.  
16. The slides were covered with Super Enhancer for 30 minutes.  
17. The slides were washed in citrate buffer for 5 minutes x 2 changes.  
18. The slides were covered with SS Label for 30 minutes.  
19. Wash in citrate buffer for 5 minutes x 2 changes.  
20. DAB substrate was prepared by diluting 1 drop of DAB chromogen to 1 ml  
      of  DAB buffer.  
21. DAB substrate solution was applied on the sections for 8 minutes.  
22. Wash with citrate buffer solution for 5 minutes x 2 changes.  
23. The slides are washed well in running tap water for 5 minutes.  
24. The sections were counterstained with Hematoxylin stain for 2 seconds   
       (1 dip).  
25. The slides are washed in running tap water for 3 minutes.  
26. The slides are air dried, cleared with xylene and mounted with DPX 
 
 
 
 
 
  
 
 
 
 
MASTER CHART 
 
s.no HPE no Age Sex P/D site Gross Size Histological type Lauren Grade Depth LVI PNI Lymph LN stage MUC1
1 3424/13 47 1 1 1 3 3 1 1 2 2 A A A 1 2
2 3468/13 78 2 1 1 3 2.5 1 2 2 3 A A A 2 4
3 3708/13 50 1 2 1 3 7 1 1 2 3 A A A 2 4
4 4191/13 56 1 1 2 3 3 2 1 2 3 P A A 2 4
5 4192/13 55 1 1 1 4 4.5 3 2 3 2 A A P 2 3
6 4939/13 60 1 2 1 3 7 1 1 2 3 P A P 2 4
7 5222/13 70 1 2 1 4 6 3 2 3 3 A A A 2 4
8 5335/13 70 1 1 3 4 5 3 2 2 3 A A A 1 3
9 5641/13 41 1 4 1 1 5 4 2 3 3 P A A 2 4
10 5747/13 57 1 3 1 3 5 6 _ _ 3 P A P 2 4
11 5828/13 38 2 1 1 1 6 7 _ _ _ A A A 1 _
12 6154/13 61 1 2 2 3 7 1 1 2 1 P A P 2 2
13 6952/13 41 2 1 1 4 1.5 3 2 2 3 A A A 1 3
14 7045/13 35 1 1 2 4 4 3 2 3 3 P A A 3 5
15 7998/13 66 1 2 1 1 3 1 1 2 4 P A A 2 6
16 8091/13 50 1 1 1 3 3.5 1 1 3 3 P A A 2 4
17 8307/13 57 1 2 2 3 2 1 1 2 2 A A A 3 4
18 8427/13 78 1 1 1 4 8 2 1 3 2 P A A 2 3
19 8468/13 64 1 1 1 1 2.5 1 1 2 3 A A P 2 4
20 8603/13 65 1 2 1 3 8 1 1 2 2 P A A 2 3
21 8684/13 76 1 2 2 2 2.5 1 1 1 2 A A A 1 2
22 8837/13 57 1 1 1 2 2 3 2 3 4 P A A 3 6
23 9063/13 54 2 2 1 1 3 1 1 2 3 A A A 2 4
24 9074/13 46 2 1 1 2 6.5 1 1 1 3 A A A 3 5
25 9077/13 37 1 1 1 2 2.5 1 1 2 2 P A A 2 3
26 9119/13 65 2 2 1 1 6 1 1 2 2 A A A 1 2
27 9142/13 48 1 1 1 1 4 1 1 2 3 P A A 2 4
28 9215/13 48 1 1 2 2 5 1 1 2 3 P A A 2 4
29 9631/13 56 2 2 2 3 7 1 1 3 3 P A A 2 4
30 9634/13 75 1 1 1 1 2 1 1 2 3 P A A 2 4
31 9741/13 65 1 1 1 3 2.5 1 1 2 2 P A A 2 3
32 9969/13 57 1 1 1 2 10 5 1 2 3 P A A 3 5
33 10137/13 55 2 2 1 2 4 1 1 2 3 P A P 2 4
34 10252/13 39 2 1 1 1 5 1 1 2 3 P A A 2 4
35 10478/13 42 2 1 2 2 2 1 1 3 3 A A A 1 3
36 10711/13 56 1 1 1 1 4 4 2 3 3 P A A 2 4
s.no HPE no Age Sex P/D site Gross Size Histological type Lauren Grade Depth LVI PNI Lymph LN stage MUC1
37 10914/13 65 1 2 1 3 3 1 1 2 3 P A A 1 3
38 11272/13 65 1 1 1 3 2.5 1 1 2 3 P A A 2 4
39 297/14 66 1 1 1 4 3 3 2 3 3 p A A 1 3
40 353/14 55 2 3 2 3 6 1 1 3 3 P A A 1 3
41 713/14 63 2 2 1 3 4 2 1 3 2 A A A 2 3
42 860/14 58 1 3 1 3 4 2 1 2 4 A A A 2 6
43 862/14 66 1 1 1 1 4 3 2 2 1 A A A 1 1
44 872/14 58 2 3 1 3 2 1 1 3 3 A A A 1 3
45 993/14 54 1 1 1 2 4 1 1 1 4 P P P 2 6
46 1106/14 40 1 2 2 3 7 2 1 2 3 A A A 1 3
47 1249/14 62 1 1 1 4 6 3 2 3 3 A A A 1 3
48 1364/14 26 1 1 1 1 3.5 1 1 2 3 P A A 3 5
49 1585/14 65 1 5 1 3 5.5 1 1 2 2 A A P 2 3
50 1805/14 60 2 1 2 3 8 5 1 1 3 A A A 1 3
51 1810/14 40 1 1 3 3 6.5 2 1 2 4 P P A 2 6
52 1910/14 65 2 1 5 2 6 1 1 2 3 A A A 2 4
53 2020/14 50 2 1 1 2 2.5 4 2 2 3 A A A 2 4
54 2024/14 20 1 5 1 3 3 2 1 3 3 A A A 2 4
55 2379/14 40 1 5 1 2 9 1 1 1 3 A A A 1 3 _
56 2499/14 46 2 1 4 1 7 8 _ 1 3 P A A 2 4
57 2520/14 40 2 1 2 1 8 1 1 3 3 A A A 1 3
58 2551/14 60 2 5 1 2 6 2 1 2 3 A A A 1 3
59 3423/14 65 2 2 4 3 6 1 1 1 4 P A A 2 6
60 3532/14 66 1 1 1 3 5 1 1 1 3 A A A 1 3
61 3561/14 55 2 1 1 4 7 3 2 3 3 A A A 1 3
62 3619/14 59 1 1 1 3 11 1 1 2 3 A A A 1 3 3+
63 3633/14 65 1 5 1 2 5 1 1 3 4 A P A 2 6
64 3793/14 55 1 1 1 2 6 1 1 2 4 A A A 2 6
65 3833/14 60 2 1 1 3 1 1 1 2 2 A A A 1 2 _
66 4145/14 45 1 5 1 3 4 1 1 2 4 P P P 2 6
67 4409/14 41 1 2 2 2 7 4 2 3 3 A A A 1 3
68 4618/14 62 1 1 1 2 4 1 1 2 4 A A A 1 4 2+
69 5723/14 57 2 1 1 3 3 4 2 3 2 A A A 1 2
70 6098/14 75 1 1 1 2 4.5 1 1 2 3 A A A 1 3
71 6451/14 64 1 3 1 2 2 4 2 3 3 A A A 1 3
72 6461/14 36 1 1 1 3 5 1 1 3 3 A P P 2 4 1+
s.no HPE no Age Sex P/D site Gross Size Histological type Lauren Grade Depth LVI PNI Lymph LN stage MUC1
73 6605/14 53 1 1 2 2 3 3 2 3 2 A A A 1 2 _
74 7311/14 55 1 2 4 2 4 1 1 2 3 A A A 1 3 2+
75 7350/14 51 1 1 3 1 5 3 2 3 3 A A A 2 4 3+
76 7546/14 71 2 2 1 3 9 1 1 3 3 A A A 1 3 2+
77 7675/14 50 1 1 1 3 5 1 1 2 3 A A A 2 4 3+
78 7765/14 45 1 1 1 2 9 1 1 2 3 A A A 1 3 _
79 8060/14 54 1 3 1 3 5 1 1 2 4 P A A 2 6 1+
80 8227/14 70 1 1 1 1 6 1 1 2 3 A A A 1 3 1+
81 8640/14 40 1 5 1 3 5 1 1 3 2 A A P 2 3 _
82 8676/14 57 1 1 1 2 10 2 1 3 3 P A A 1 3 2+
83 8753/14 30 2 2 1 2 11 1 1 3 3 P A P 2 4 1+
84 8969/14 70 1 1 1 2 3 1 1 2 3 P A A 2 4 2+
85 9068/14 51 1 1 1 4 5 5 1 2 2 A A A 1 2 _
86 9117/14 42 2 1 1 3 6 1 1 3 3 A A A 2 4 _
87 9186/14 50 1 2 2 4 5 4 2 3 1 A A A 1 1
88 9322/14 60 1 1 1 3 5 4 2 3 3 A A A 2 4
89 10095/14 65 1 1 1 2 3.5 1 1 2 2 A A A 1 2 1+
90 10421/14 55 2 2 1 4 3 1 1 2 3 P A P 2 4 _
91 10646/14 61 1 2 4 2 3 1 1 2 3 P A P 2 4 1+
92 10864/14 46 2 3 2 4 4 3 2 3 4 A P P 2 6 1+
93 10869/14 30 1 1 2 1 12 1 1 3 4 P A A 2 6 3+
94 11356/14 55 2 5 1 4 4 1 1 2 3 P A P 2 4 _
95 11361/14 84 1 1 1 2 4 1 1 3 3 P A P 2 4 1+
96 11421/14 70 1 1 2 3 7 1 1 1 3 A A A 2 4 _
97 11476/14 60 1 2 1 2 3.5 1 1 3 3 A A A 1 3
98 11776/14 74 2 1 2 3 3 1 1 2 4 P A P 1 4 1+
99 11993/14 56 1 5 1 3 6 1 1 2 3 A A A 2 4 _
100 16/15 70 1 1 1 4 4 3 1 1 3 A A P 1 3 _
101 117/15 62 1 1 2 2 4.5 1 1 2 4 P A P 2 6 2+
102 206/15 33 1 1 1 3 4 1 1 2 3 A P P 1 3 _
103 603/15 60 1 3 1 3 10 1 1 2 2 P P A 1 2 1+
104 697/15 77 1 2 1 3 6 1 1 3 3 P P A 2 4 1+
105 1090/15 55 2 1 1 1 7 3 2 3 3 A P A 3 5 3+
106 1094/15 62 1 1 2 2 2 2 1 2 3 P A A 3 5 1+
107 1252/15 65 1 1 1 3 7 1 1 2 2 P A A 3 4 _
108 1628/15 43 1 1 2 2 6.5 1 1 2 3 P A P 3 5 2+
s.no HPE no Age Sex P/D site Gross Size Histological type Lauren Grade Depth LVI PNI Lymph LN stage MUC1
109 1644/15 64 2 1 2 1 6.5 1 1 1 3 A A A 2 4 _
110 2288/15 48 1 1 1 3 7 5 1 1 3 P A P 1 3 1+
111 2555/15 30 2 2 1 2 3 2 1 3 4 P P P 2 6 3+
112 2635/15 76 2 2 4 3 6 1 1 3 4 P P P 2 6 _
113 3752/15 75 1 1 1 2 6.5 1 1 2 3 P A A 1 3 _
114 3833/15 45 1 1 1 3 7 1 1 2 2 A A A 1 2 _
115 3865/15 58 1 1 1 4 5 3 2 3 3 A A A 3 5 3+
116 4109/15 52 2 1 1 3 5 1 1 3 4 A A A 2 6 3+
117 4319/15 60 1 1 1 2 6 1 1 3 4 A A A 2 6 1+
118 4572/15 65 1 3 2 3 4 2 1 1 3 A A P 1 3 1+
119 4648/15 45 2 2 1 3 4 1 1 1 3 A A A 1 3 1+
120 4846/15 32 2 2 2 2 4 1 1 2 3 A A A 1 3 1+
                                          
KEY TO MASTER CHART 
SEX 
Male-1 
Female-2 
          PROCEDURE DONE 
Subtotal gastrectomy-1 
Total gastrectomy-2 
Palliative gastrectomy-3 
Partial gastrectomy-4 
Distal gastrectomy-5 
SITE 
Pyloro-antrum-1 
Body-2 
Fundus-3 
OG junction-4 
Cardia-5 
GROSS(Bormann classification) 
TYPE 1-1 
TYPE 2-2 
TYPE 3-3 
TYPE 4-4  
HISTOLOGICAL TYPE 
Tubular-1 
Papillary-2 
Diffuse-3 
Signet ring-4 
Mucinous-5 
Lymphoepithelial-6 
Lymphoma-7 
Squamous cell carcinoma-8 
LAUREN’S classification 
Intestinal type-1 
Diffuse type-2 
GRADING 
G1-Well differentiated-1 
G2-Moderately differentiated-2 
G3-Poorly differentiated-3 
DEPTH OF THE TUMOR 
T1-1 
T2-2 
T3-3 
T4-4 
LYMPHNODE 
N0-1 
N1-2 
N2-3 
N3-4 
STAGING 
IA-1 
IB-2 
II-3 
IIIA-4 
IIIB-5 
IV-6 
 
